Inclusion Criteria:

          1. Signed written informed consent granted

          2. Men or women ≥18 years of age

          3. Histologically or cytologically confirmed, locally advanced, inoperable, or metastatic
             solid tumors. Subjects eligible for enrollment in the Expanded Cohort must have
             documented and/or confirmed FGFR genetic alterations, including iCCA with FGFR2 gene
             fusion.

          4. Failure to respond to standard therapy, or for whom standard therapy does not exist.

          5. Evaluable or measurable disease

          6. Archival and/or fresh biopsy tissue samples must be available prior to the first dose
             of the study drug

          7. Life expectancy ≥ 12 weeks

          8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          9. Hemoglobin (Hgb) ≥ 9.0 g/dL

         10. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L

         11. Platelet count ≥ 100 x 10^9/L

         12. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (≤ 2 x ULN for subjects with
             cholangiocarcinoma)

         13. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 × ULN (≤ 5 x ULN for
             subjects with liver metastases)

         14. Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 60 mL/min/1.73 m^2 for subjects
             with creatinine levels above institutional normal

         15. Albumin ≥ 2.8 g/dL

         16. INR 0.8 to ULN or ≤ 3 for subjects receiving anticoagulant therapy

         17. Men or women of child-producing potential must agree to use double-barrier
             contraceptive measures, oral contraception, or avoid intercourse during the study and
             for 90 days after the last dose of study drug

         18. Women of childbearing potential must have a negative serum pregnancy test during
             Screening Period and within 48 hours of the first dose of derazantinib.

        Exclusion Criteria:

          1. Anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted therapy,
             or investigational agents within four weeks or five times of the drug half life,
             whichever is longer, of the first dose of derazantinib

          2. Major surgery or radiation therapy within four weeks of the first dose of derazantinib

          3. Previous treatment with FGFR inhibitors

          4. History of allergic reactions attributed to compounds of similar chemical or
             biological composition as derazantinib

          5. Unable or unwilling to swallow the complete daily dose of derazantinib

          6. Clinically unstable central nervous system (CNS) metastasis

          7. History of myocardial infarction (MI) or congestive heart failure defined as Class II
             to IV per the New York Heart Association classification within 6 months of the first
             dose of derazantinib (MI occurring >6 months of the first dose of derazantinib will be
             permitted)

          8. Significant GI disorder(s) that could interfere with the absorption, metabolism, or
             excretion of derazantinib (e.g. Crohn's disease, ulcerative colitis, extensive gastric
             resection)

          9. History and/or current evidence of clinically relevant ectopic
             mineralization/calcification

         10. Previous malignancy within 2 years prior to the first dose of derazantinib, except
             curatively treated non-melanoma skin cancer, carcinoma in-situ of the breast or
             cervix, or superficial bladder tumors

         11. Known human immunodeficiency virus (HIV) infection

         12. Concurrent uncontrolled illness not related to cancer, including but not limited to:

               -  Psychiatric illness/substance abuse/social situation that would limit compliance
                  with study requirements.

               -  Uncontrolled diabetes mellitus

         13. Blood transfusion within 5 days of the blood draw being used to confirm eligibility

         14. Pregnant or breastfeeding